Published in Blood Weekly, November 30th, 2006
The improvement in results was mainly due to increased consolidated net sales and improved gross margin percentages.
Consolidated net sales for the quarter ended September 30, 2006 were $52.4 million, an increase of 9.7% from the quarter ended September 30, 2005. Biotechnology net sales for the quarter ended September 30, 2006 were $35.9 million, an increase of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.